Gilead, Gritstone Aim To Develop HIV Cure In Vaccine Collaboration

Gilead Sciences, Inc. GILD said Monday that it has entered into a collaboration, option and license agreement with Gritstone Oncology Inc GRTS to develop a vaccine-based immunotherapy that could serve as a curative treatment for HIV infection.

What Happened: The two companies will develop a HIV-specific therapeutic vaccine using Gritstone's proprietary prime-boost vaccine platform that would use antigens developed by Gilead, the statement said.

Gritstone's vaccine platform comprises self-amplifying mRNA and adenoviral vectors.

"Curing HIV remains the ultimate aspiration for Gilead's HIV research and development efforts. Gritstone's vaccine technology has the potential to educate the immune system to specifically recognize and destroy HIV-infected cells by leveraging SAM and adenoviral vectors," Diana Brainard, a Gilead senior vice president for virology therapeutics, said in a statement. 

Related Link: Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates

The Gilead-Gritstone Deal Terms: The agreement provides for Gilead making a $60-million payment to Gritstone at closing, which consists of a $30-million upfront payment and a $30-million equity investment at premium.

Gilead will conduct the Phase 1 study and also hold an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1 study.

If Gilead exercises the option and if certain clinical, regulatory and commercial milestones are achieved, Gritstone will be eligible to receive up to an additional $725 million.

The smaller biopharma also stands to receive mid-single-digit to low double-digit tiered royalties on net sales upon commercialization.

Why It's Important: Gilead has a mature HIV portfolio. The company is now testing different monotherapy and combo options for treating the disease.

In premarket trading, Gilead shares were rising 0.41% to $65.87 and Gritstone was soaring 21.55% to $22.

Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.